Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine + dexmedetomidine for postoperative depression and recovery in breast cancer surgery
ChiCTR2400090902Phase 2Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of esketamine and dexmedetomidine in breast cancer and major depressive disorder (MDD) (4 arms), sponsored by The First Hospital of Fujian Medical University. Primary endpoints: Self-rating Depression Scale (SDS) score and Incidence of agitation, delirium and other adverse reactions. Started Oct 2024; status: recruiting.
02
Drugs
esketaminedexmedetomidine
03
Conditions
breast cancermajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2400090902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090902.